A phase 3 pivotal trial assessing EO-2002
Latest Information Update: 03 May 2024
Price :
$35 *
At a glance
- Drugs EO 2002 (Primary)
- Indications Corneal disorders
- Focus Registrational; Therapeutic Use
- 03 May 2024 New trial record
- 30 Apr 2024 According to Emmecell media release, this phase 3 pivotal study is planned for the first quarter of 2025